Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sujata M Bhavnani

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Current Opinion in Pharmacology|December 17, 2017
Editorial overview: Use of PK-PD for antibacterial drug development: decreasing risk and paths forward for resistant pathogensSujata M Bhavnani, John H Rex
Diagnostic Microbiology and Infectious Disease|September 25, 2007
Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumoniaSujata M Bhavnani, Paul G Ambrose
Pharmacotherapy|May 19, 2005
Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safetySujata M Bhavnani, David R Andes
Current Opinion in Pharmacology|November 21, 2017
Clinical pharmacokinetic-pharmacodynamic analyses: a critical element for developing antibacterial agentsSujata M Bhavnani, Jeffrey P Hammel
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2023
The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus ComplexJohn P O'Donnell, Sujata M Bhavnani
Current Opinion in Pharmacology|November 13, 2017
Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selectionMichael Trang, Michael N Dudley, Sujata M Bhavnani
Diagnostic Microbiology and Infectious Disease|December 8, 2004
The inoculum effect: fact or artifact?William A Craig, Sujata M Bhavnani, Paul G Ambrose
The Annals of Pharmacotherapy|March 16, 2002
Pharmacodynamics in the evaluation of drug regimensSujata M Bhavnani, Paul G Ambrose, Ronald N Jones
Infectious Disease Clinics of North America|January 9, 2004
Clinical pharmacodynamics of quinolonesPaul G Ambrose, Sujata M Bhavnani, Robert C Owens
Open Forum Infectious Diseases|July 16, 2020
A Broken Antibiotic Market: Review of Strategies to Incentivize Drug DevelopmentSujata M Bhavnani, Kevin M Krause, Paul G Ambrose
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Current Opinion in Pharmacology|December 17, 2017
Editorial overview: Use of PK-PD for antibacterial drug development: decreasing risk and paths forward for resistant pathogensSujata M Bhavnani, John H Rex
Diagnostic Microbiology and Infectious Disease|September 25, 2007
Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumoniaSujata M Bhavnani, Paul G Ambrose
Pharmacotherapy|May 19, 2005
Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safetySujata M Bhavnani, David R Andes
Current Opinion in Pharmacology|November 21, 2017
Clinical pharmacokinetic-pharmacodynamic analyses: a critical element for developing antibacterial agentsSujata M Bhavnani, Jeffrey P Hammel
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2023
The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus ComplexJohn P O'Donnell, Sujata M Bhavnani
Current Opinion in Pharmacology|November 13, 2017
Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selectionMichael Trang, Michael N Dudley, Sujata M Bhavnani
Diagnostic Microbiology and Infectious Disease|December 8, 2004
The inoculum effect: fact or artifact?William A Craig, Sujata M Bhavnani, Paul G Ambrose
The Annals of Pharmacotherapy|March 16, 2002
Pharmacodynamics in the evaluation of drug regimensSujata M Bhavnani, Paul G Ambrose, Ronald N Jones
Infectious Disease Clinics of North America|January 9, 2004
Clinical pharmacodynamics of quinolonesPaul G Ambrose, Sujata M Bhavnani, Robert C Owens
Open Forum Infectious Diseases|July 16, 2020
A Broken Antibiotic Market: Review of Strategies to Incentivize Drug DevelopmentSujata M Bhavnani, Kevin M Krause, Paul G Ambrose
Pageof 12